Results 11 to 20 of about 4,201,128 (311)

Cardiac Failure Associated with Medical Therapy of Benign Prostatic Hyperplasia: A Population Based Study

Journal of Urology, 2021
Purpose: Increased risk of cardiac failure with α-blockers in hypertension studies and 5-alpha reductase inhibitors in prostate studies have raised safety concerns for long term management of benign prostatic hyperplasia.
A. Lusty, D. Siemens, Mina Tohidi, M. Whitehead, J. Tranmer, J. Nickel, Stuart St   +6 more
semanticscholar   +1 more source

Cardiac Energy Metabolism in Heart Failure

Circulation Research, 2021
Alterations in cardiac energy metabolism contribute to the severity of heart failure. However, the energy metabolic changes that occur in heart failure are complex and are dependent not only on the severity and type of heart failure present but also on ...
G. Lopaschuk, Qutuba G. Karwi, R. Tian, A. Wende, E. Abel   +4 more
semanticscholar   +1 more source

3D bioprinting and its potential impact on cardiac failure treatment: An industry perspective

APL Bioengineering, 2020
3D printing technologies are emerging as a disruptive innovation for the treatment of patients in cardiac failure. The ability to create custom devices, at the point of care, will affect both the diagnosis and treatment of cardiac diseases.
R. Birla, Stuart K. Williams
semanticscholar   +1 more source

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.

New England Journal of Medicine, 2020
BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown.
J. Teerlink, R. Diaz, G. Felker, J. McMurray, M. Metra, S. Solomon, K. Adams, I. Anand, Alexandra Arias-Mendoza, T. Biering-Sørensen, M. Böhm, D. Bonderman, J. Cleland, R. Corbalán, M. Crespo-Leiro, U. Dahlström, L. E. Echeverría, J. Fang, G. Filippatos, C. Fonseca, E. Goncalvesova, A. Goudev, J. Howlett, D. Lanfear, Jing Li, M. Lund, P. Macdonald, V. Mareev, S. Momomura, E. O’Meara, A. Parkhomenko, P. Ponikowski, F. Ramires, P. Serpytis, K. Sliwa, J. Špinar, T. Suter, J. Tomcsányi, H. Vandekerckhove, D. Vinereanu, A. Voors, M. Yılmaz, F. Zannad, L. Sharpsten, J. Legg, C. Varin, Narimon Honarpour, Siddique A Abbasi, F. Malik, C. Kurtz   +49 more
semanticscholar   +1 more source

The effect of cardiac resynchronization on morbidity and mortality in heart failure.

New England Journal of Medicine, 2005
BACKGROUND Cardiac resynchronization reduces symptoms and improves left ventricular function in many patients with heart failure due to left ventricular systolic dysfunction and cardiac dyssynchrony. We evaluated its effects on morbidity and mortality.
J. Cleland, J. Daubert, E. Erdmann, N. Freemantle, D. Gras, L. Kappenberger, L. Tavazzi   +6 more
semanticscholar   +1 more source

Cardiac Failure and Benzodiazepines [PDF]

Sleep, 1993
Nine patients with stable cardiac failure and mean left ventricular ejection fraction of 30% were investigated. All had previously been prescribed a benzodiazepine hypnotic by their home physicians, but the medication had been discontinued for at least 1 month.
Riccardo Stoohs, Jerald H Simmons, Alex Clerk, Christian Guilleminault, Michael Labanowski   +4 more
openaire   +3 more sources

Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.

New England Journal of Medicine, 2004
BACKGROUND We tested the hypothesis that prophylactic cardiac-resynchronization therapy in the form of biventricular stimulation with a pacemaker with or without a defibrillator would reduce the risk of death and hospitalization among patients with ...
M. Bristow, L. Saxon, J. Boehmer, S. Krueger, D. Kass, T. De Marco, P. Carson, L. DiCarlo, D. DeMets, B. G. White, Dale W Devries, A. Feldman   +11 more
semanticscholar   +1 more source

Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure

Circulation: Heart Failure, 2020
Supplemental Digital Content is available in the text. Background: Although empagliflozin was shown to profoundly reduce cardiovascular events in diabetic patients and blunt the decline in cardiac function in nondiabetic mice with established heart ...
Nikole J. Byrne, Nobutoshi Matsumura, Zaid H Maayah, M. Ferdaoussi, S. Takahara, Ahmed M Darwesh, Jody L. Levasseur, James Won Suk Jahng, D. Vos, N. Parajuli, A. El-Kadi, B. Braam, M. Young, S. Verma, P. Light, G. Sweeney, J. Seubert, J. Dyck   +17 more
semanticscholar   +1 more source

The risk of cardiac failure following metal-on-metal hip arthroplasty

The Bone & Joint Journal, 2018
Aims The aim of this study was to determine whether patients with metal‐on‐metal (MoM) arthroplasties of the hip have an increased risk of cardiac failure compared with those with alternative types of arthroplasties (non‐MoM).
S. Sabah, J. Moon, S. Jenkins-Jones, C. Morgan, C. Currie, J. Wilkinson, M. Porter, G. Captur, J. Henckel, N. Chaturvedi, P. Kay, J. Skinner, A. Hart, C. Manisty   +13 more
semanticscholar   +1 more source

Multidisciplinary Cardiac Rehabilitation and Long-Term Prognosis in Patients With Heart Failure

Circulation: Heart Failure, 2020
Supplemental Digital Content is available in the text. Background: Exercise-based cardiac rehabilitation (CR) improves health-related quality of life and exercise capacity in patients with heart failure (HF).
K. Kamiya, Yukihito Sato, Tetsuya Takahashi, Miyuki Tsuchihashi-Makaya, N. Kotooka, Toshimi Ikegame, T. Takura, Takanobu Yamamoto, M. Nagayama, Y. Goto, S. Makita, M. Isobe   +11 more
semanticscholar   +1 more source